General Information of Drug (ID: DMZMQDN)

Drug Name
NK-1001 Drug Info
Synonyms NNYK-1001; NYK-1001
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
3040841
CAS Number
CAS 53025-93-7
TTD Drug ID
DMZMQDN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AG-858 DMNQ5T2 leukaemia 2A60-2B33 Phase 2 [3]
AEG-33773 DMSBLOU Diabetic neuropathy 8C0Z Phase 2 [4]
Enkastim-ev DMGLHYU Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Minnelide 001 DM5VEN9 Gastric adenocarcinoma 2B72 Phase 1 [6]
BRX-005 DMTDWIE Diabetic foot ulcer BD54 Phase 1 [7]
Minnelide DMDER9S Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
AG-707 DM7PLMJ Herpes simplex virus infection 1F00 Phase 1 [9]
H-103 DMRCHOU Metastatic malignant neoplasm 2D50-2E09 Phase 1 [10]
Bimoclomol DMOP95G Diabetic complication 5A2Y Discontinued in Phase 2 [11]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
OGX-427 DMJTU8D Bladder cancer 2C94 Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 27 (HSP27) TTMG98T HSPB3_HUMAN Modulator [2]
Heat shock protein 70 (HSP70) TTHYBIX HS71A_HUMAN; HS71B_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033456)
2 Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21.
3 Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265.
4 Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009
5 Company report (Multimmune)
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41.
10 A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82.
11 Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002 Jan 18;435(1):73-7.
12 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.